Genmab A (GMAB) Exchange Rate Effect (2023 - 2026)
Genmab A's (GMAB) quarterly Exchange Rate Effect came in at -$11.0 million in Q1 2026, down 237.5% YoY from $8.0 million in Q1 2025, and down 257.14% on a QoQ basis from $7.0 million in Q3 2025.
Genmab A (GMAB) Exchange Rate Effect (2023 - 2026) Analysis & Trends
Genmab A (GMAB) has 4 years of Exchange Rate Effect data on file, last reported at -$11.0 million in Q1 2026.
- Quarterly Exchange Rate Effect fell 237.5% year-over-year to -$11.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (down 73.08% YoY) and the FY2025 annual result came in at $3.0 million, down 95.24% from the prior year.
- Exchange Rate Effect slipped to -$11.0 million in Q1 2026, from $7.0 million in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $34.0 million in Q3 2024 to a low of -$15.0 million in Q2 2024.
- A 4-year average of $1.6 million and a median of $1.0 million in 2024 frame the typical range for Exchange Rate Effect.
- Annual changes were most pronounced in 2025 — Exchange Rate Effect surged 900.0% — and 2026, when it tumbled 237.5%.
- Tracing GMAB's Exchange Rate Effect over 4 years: stood at -$12.0 million in 2023, then jumped by 383.33% to $34.0 million in 2024, then tumbled by 79.41% to $7.0 million in 2025, then plunged by 257.14% to -$11.0 million in 2026.
- The last three Exchange Rate Effect figures came in at -$11.0 million (Q1 2026), $7.0 million (Q3 2025), and $3.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.00 Mn |
| Jun 30, 2026 | 4.00 Mn |
| Mar 31, 2026 | -11.00 Mn |
| Mar 31, 2026 | -11.00 Mn |
| Sep 30, 2025 | 7.00 Mn |
| Sep 30, 2025 | 7.00 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Sep 30, 2024 | 34.00 Mn |
| Sep 30, 2024 | 34.00 Mn |
| Jun 30, 2024 | -15.00 Mn |
| Jun 30, 2024 | -15.00 Mn |
| Mar 31, 2024 | -1.00 Mn |
| Mar 31, 2024 | -1.00 Mn |
| Dec 31, 2023 | -12.00 Mn |
| Dec 31, 2023 | -12.00 Mn |